newsfilter
← Earnings
Earnings Releases·

Allogene Therapeutics — Third Quarter 2026 Earnings Summary

  • Q3 2026 net loss narrowed to $50.4 million ($0.15/share) from $41.4 million ($0.19/share) in Q3 2025, while total operating expenses rose to $54.8 million from $44.9 million year-over-year.
  • Cash, equivalents, and investments increased to $388.9 million as of September 30, 2026, from $258.3 million at year-end 2025, extending the projected cash runway into 2029.
  • Full-year 2026 operating expense guidance is set at approximately $165 million, with GAAP expenses expected around $225 million including non-cash stock-based compensation.
  • Clinical progress includes continued enrollment momentum for the ALPHA3 trial (targeting completion by year-end 2027) and upcoming data presentations for ALLO-329 at ACR Convergence and ALLO-316 findings from SITC 2026.
  • Strategic initiatives include the appointment of a Vice President for Market Access to drive payer coverage and plans to host an investor event at ASH to address barriers to CAR T adoption in community practices.
Company
ALLOGENE THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology